IRONWOOD PHARMACEUTICALS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $3.06 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-02-22
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.63M.
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $682.00K.
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $465.00K.
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $289.00K.
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $3.06M, a 2708.26% increase from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $109.00K.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $2.31M derived: sum of 2 quarters · filed 2018-02-22 | $2.77M derived: sum of 3 quarters · filed 2018-02-22 | $3.06M 10-K · filed 2018-02-22 |
| 2017-09-30 | $682.00K 10-Q · filed 2017-11-02 | $1.15M derived: sum of 2 quarters · filed 2017-11-02 | $1.44M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $465.00K 10-Q · filed 2017-08-03 | $754.00K 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | $289.00K 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $109.00K 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |